Compare ASPI & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPI | OPK |
|---|---|---|
| Founded | 2021 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.0M | 921.2M |
| IPO Year | 2022 | 2011 |
| Metric | ASPI | OPK |
|---|---|---|
| Price | $7.06 | $1.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $12.00 | $1.60 |
| AVG Volume (30 Days) | ★ 5.9M | 2.7M |
| Earning Date | 04-10-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $23,849,000.00 | ★ $606,879,000.00 |
| Revenue This Year | $68.41 | N/A |
| Revenue Next Year | $126.69 | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 475.48 | N/A |
| 52 Week Low | $3.92 | $0.98 |
| 52 Week High | $14.49 | $1.60 |
| Indicator | ASPI | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 54.41 | 65.70 |
| Support Level | $5.16 | $1.25 |
| Resistance Level | $8.41 | $1.54 |
| Average True Range (ATR) | 0.69 | 0.06 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 43.98 | 47.37 |
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.